---
title: "Humira (adalimumab), all indications: Drug interactions questions"
description: "Drug interactions questions on Humira (adalimumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Humira have? Does Humira affect warfarin or other CYP450 substrate drugs? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/humira/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Humira (adalimumab), all indications: Drug interactions questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Humira](https://www.rxabbvie.com/pdf/humira.pdf)  
Indication pages: [Rheumatoid arthritis](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis)

## Drug interactions

<a id="humira-drug-interactions"></a>

### What drug interactions does Humira have?

> “Abatacept: Increased risk of serious infection. (5.1, 5.11, 7.2)  
> • Anakinra: Increased risk of serious infection. (5.1, 5.7, 7.2)  
> • Live vaccines: Avoid use with HUMIRA. (5.10, 7.3)”

Source: [HUMIRA: Prescribing information, page 2, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=2)

> “7.2 Biological Products  
> In clinical studies in patients with RA, an increased risk of serious infections has been observed 
> with the combination of TNF blockers with anakinra or abatacept, with no added benefit; 
> therefore, use of HUMIRA with abatacept or anakinra is not recommended in patients with RA 
> [see Warnings and Precautions (5.7, 5.11)]. A higher rate of serious infections has also been 
> observed in patients with RA treated with rituximab who received subsequent treatment with a 
> TNF blocker. There is insufficient information regarding the concomitant use of HUMIRA and 
> other biologic products for the treatment of RA, PsA, AS, CD, UC, Ps, HS and UV. Concomitant 
> administration of HUMIRA with other biologic DMARDS (e.g., anakinra and abatacept) or other 
> TNF blockers is not recommended based upon the possible increased risk for infections and 
> other potential pharmacological interactions.”

Source: [HUMIRA: Prescribing information, page 23, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=23)

<a id="humira-cyp450-warfarin"></a>

### Does Humira affect warfarin or other CYP450 substrate drugs?

> “7.4 Cytochrome P450 Substrates 
> The formation of CYP450 enzymes may be suppressed by increased concentrations of cytokines 
> (e.g., TNFα, IL-6) during chronic inflammation. It is possible for a molecule that antagonizes 
> cytokine activity, such as adalimumab, to influence the formation of CYP450 enzymes. Upon 
> initiation or discontinuation of HUMIRA in patients being treated with CYP450 substrates with a 
> narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., 
> cyclosporine or theophylline) is recommended and the individual dose of the drug product may 
> be adjusted as needed.”

Source: [HUMIRA: Prescribing information, page 23, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=23)

## Related pages
- [Medical information: Humira (adalimumab): All indications](https://www.evicenter.com/medical-information/humira)
- [Indication](https://www.evicenter.com/medical-information/humira/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/humira/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/humira/safety)
- [Specific populations](https://www.evicenter.com/medical-information/humira/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/humira/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/humira/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/humira/access-and-coverage)
